Trial Profile

Completion rate, Bictegravir trough concentration, cytokine profile, and virologic response in people living with HIV (Plwh) with latent TB infection (LTBI) who received one-month regimen of daily rifapentine plus isoniazid (1HP) and BIC/FTC/TAF concurrently

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Isoniazid (Primary) ; Rifapentine (Primary)
Indications HIV infections
Focus Pharmacokinetics; Therapeutic Use

21 Apr 2021 New trial record
10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com